Taiho Oncology gets US FDA nod for Lonsurf refractory colorectal cancer drug
The company carried out the worldwide Phase III RECOURSE trial in 800 patients who were earlier treated for mCRC. It met the primary efficacy endpoint of statistically significant
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.